Abdolreza Haririan, MD
Nephrology · Baltimore, MDNPI 1497708747
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,150 of the $4,447 with a category attached, or 93.3%. Mallinckrodt Enterprises LLC accounts for 94.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $4,212 and has fallen 96.7% since, to $139 in 2025.
Across 12 payments — averaging $370.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$4K
- Calliditas Therapeutics US Inc.$75
- Takeda Pharmaceuticals U.S.A., Inc.$50
- Merck$48
- Veloxis Pharmaceuticals, Inc.$39
- Eurofins Viracor, LLC$22
Across 10 payments — averaging $3320.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$22K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
What the payments were for
- Consulting fees$4,15093%
- Travel & lodging$341%
- Food & beverage$2636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 3 | $4,212 |
| Calliditas Therapeutics US Inc. | 2 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Merck | 3 | $48 |
| Veloxis Pharmaceuticals, Inc. | 1 | $39 |
| Eurofins Viracor, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$4,150
How this compares
$4,447 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NulojixBelatacept | 43 | $100,094 |
| Cinacalcet Hcl | 136 | $47,931 |
| Mycophenolic AcidMycophenolate Sodium | 54 | $15,940 |
| Tacrolimus | 108 | $15,822 |
| Sevelamer Carbonate | 20 | $5,926 |
| Mycophenolate Mofetil | 22 | $4,180 |
| Valganciclovir Hcl | 32 | $3,066 |
| Nifedipine ErNifedipine | 85 | $2,039 |
| Calcitriol | 86 | $1,630 |
| Cardura XlDoxazosin Mesylate | 11 | $1,571 |
| Entecavir | 12 | $1,458 |
| Amlodipine Besylate | 167 | $1,332 |
| Atorvastatin Calcium | 142 | $1,281 |
| Pantoprazole Sodium | 119 | $998 |
| Losartan Potassium | 104 | $892 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Baltimore
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Mohamed AttaBaltimore$65K
- Michelle EstrellaBaltimore$55K
- Zainab ObaidiBaltimore$39K
- Christopher SperatiBaltimore$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.